Clinical Trials
15 trialsNCT06390319 2026-05-01
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT06854653 2026-04-29
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Phase 2 Recruiting
NCT04984837 2026-04-20
Study of Lacutamab in Peripheral T-cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Recruiting
NCT07356245 2026-04-15
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT05996185 2026-04-14
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University
Phase 2 Recruiting
NCT06756308 2026-04-07
A Study of Enasidenib in People With T-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06716658 2025-11-18
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT03125642 2025-11-04
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT06534060 2025-10-03
MB-105 in Patients With CD5 Positive T-cell Lymphoma
March Biosciences Inc
Phase 2 Recruiting
NCT06530550 2025-08-12
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT07106723 2025-08-06
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05805605 2025-07-01
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT05313243 2025-03-20
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Yale University
Phase 2 Recruiting
NCT06151106 2025-02-19
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT02859402 2022-08-18
RRTCLAlloSCT
Keimyung University Dongsan Medical Center
Phase 2 Recruiting